Home › Orexigen: Contrave Sales Dip, Passing Belviq Still A Few Weeks Away
 

Keywords :   


Orexigen: Contrave Sales Dip, Passing Belviq Still A Few Weeks Away

2015-06-02 19:17:14| Biotech - Topix.net

Many Orexigen investors thought that this may be the week when Contrave outpaced Arena's Belviq in overall sales, but alas, the sales actually lost a bit of ground and that event is likely two or three weeks away. Contrave sales came in at a bit below 13,400 according to IMS health, and Contrave sits about 900 scripts behind the market share leader in Belviq.

Tags: sales away weeks passing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Is China's bubble tea bubble about to burst?
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Business locked in expensive AI 'arms race'
17.05Is the move to electric cars running out of power?
17.05Pornhub partners with UK child abuse fighting charity
16.05CFTC charges Agridime and its co-founders with a fraudulent cattle scheme
16.05Baleage: Advantageous for first cutting hay
More »